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How did COVID-19 pandemic changed 
the Portuguese rheumatology?
Vieira-Sousa E1, Fonseca JE1, Santos MJ2
Furthermore, some Rheumatologists, mostly resi-
dents, were reallocated to integrate the teams for emer-
gency care of COVID-19 and non-COVID-19 patients
and assisted in the care of in-ward rheumatic and non-
-rheumatic, including COVID-19 patients, according
to the needs of each Hospital/Unit in the context of the
broad reorganization of the SNS during the pandemic.   
Rheumatologists working as investigators in clinical
trials, complied with the recommendations issued by
the National Ethics Committee for Clinical Research
and National Authority of Medicines and Health Pro -
ducts which underlined the utmost priority of guaran-
teeing the trial participant safety. Preferential phone or
video calls were advised, and home delivery of experi-
mental medication (EM) was organized or in some ca -
ses, temporarily or permanent EM discontinuation,
provided that in all cases good clinical practice princi-
ples were respected and a global effort to minimize
missing data was implemented. 
The Portuguese Society of Rheumatology (SPR) en-
sured advice/recommendations for rheumatic patients
at their website and discussion webinars1.
As hydroxychloroquine, broadly used to treat
rheumatic diseases, has emerged with a potential the -
rapeutic benefit for SARS-CoV-2 infection, based on li -
mited scientific evidence, the CEROM (Colégio de
Reumatologia da Ordem dos Médicos) together with the
SPR alerted for a possible risk of rheumatic patients be-
ing deprived of their essential treatments. On the 
other hand Rheumatologists were also involved in their
hospitals in the elaboration of the rational and selection
of patients for the off-label use of treatments for
COVID-19, such as tocilizumab and anakinra.
Aiming at understanding the impact of the impact of
SARS-CoV-2 pandemic in the rheumatic patients re -
gistered at Reuma.pt, the register was updated in order
to capture SARS-CoV-2 related epidemiologic and cli -
nical information, namely disease manifestations, la -
boratory results and treatment, in a global effort inter-
We have been facing a tremendous challenge motivat-
ed by the Severe Acute Respiratory Syndrome Coron-
avirus 2 (SARS-CoV-2) pandemic. With a few days of
warning Rheumatologists had to rethink their esta -
blished conventional management of patients based on
presential appointments, to ensure ongoing adequate
care to rheumatic patients. The first operating princi-
ples were to maintain rheumatic diseases stability, treat-
ment access and protection from the potential risk of in-
fection by SARS-CoV-2.
Transforming face-to-face into virtual visits, from
hospital offices or home, was the cornerstone of this
strategy, mostly based on telephone communications,
as the availability of video-based platforms is still lim-
ited in the National Health Service (SNS). Further to as-
sessing disease activity, telephone consultations were
an opportunity to advise patients on self-isolation, self-
-protection measures and individual risk assessment; to
verify results from blood tests; to provide recommen-
dations on treatment maintenance or treatment adjus -
tments; to electronically provide prescriptions; to in-
form about the health system resources including home
delivering of medication, and to define a follow-up plan
for the pandemic period. Patients were grateful to re-
ceive their doctor’s contact in this context. 
Treatment accessibility was optimized by a large in-
crement in the utilization of electronic prescription
platforms such as PEM (Prescrição Electrónica Médica-
Serviços Partilhados do Ministério da Saúde). The hospi-
tals’ pharmacies facilitated the access to medication,
namely biologic and non-biologic disease modifying
anti-rheumatic drugs, by enlarging the period of the -
rapeutic dispensing and by sending medication to the
community pharmacies or patient’s home. 
1. Serviço de Reumatologia Hospital de Santa Maria, Centro
Hospitalar Lisboa Norte, Faculdade de Medicina, Universidade de
Lisboa, Lisboa
2. Serviço de Reumatologia, Hospital Garcia de Orta, Almada;
Faculdade de Medicina, Universidade de Lisboa, Lisboa
ACTA REUMATOL PORT. 2020;45:5-6
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
6
How did covid-19 pandemic cHanged tHe portuguese rHeumatology?
connected with the EULAR COVID-19 database
(https://www.eular.org/eular_covid19_database.cfm).
At a national level, Rheumatologists have also 
contributed to the Trace COVID-19 and SINAVE 
(Sistema Nacional de Vigilância Epidemiológica) 
platforms. 
Rheumatic Diseases Patient’s Associations were a rel-
evant player in supporting patients with several initia-
tives such as those from Associação Nacional Doentes
Artrite Reumatoide through providing the delivery of
hospital medication at patient’s homes2; the Liga Por-
tuguesa Contra as Doenças Reumáticas through coun-
seling and information at their website and newsletter3;
or the Patient’s Innovation initiative by 3D printing of
face shields to donate to at risk populations and cen-
tralizing information on useful tools for rheumatic pa-
tients at their website4. Several other initiatives were
certainly not captured in this overview and many will
be implemented in a near future.
Our expectations are that the evaluation of these
measures in the future will confirm that, in fact, we
were effective in controlling disease activity, we im-
proved the proximity with rheumatic patients through
telephone consultation and treatment accessibility, and
we did protect our patients from the potential infec-
tious risk during the pandemic period.
The question now arises on how much have we
learned from this transformation that can be applied in
the future for the care of rheumatic patients? Will we
include virtual consultations in the regular follow-up
of our patients and reduce the number of hospital vis-
its? Will we improve treatment accessibility and reduce
the number of visits to the hospital pharmacy? Will we
keep improving our patients’ literacy so that a confi-
dent non-presential interaction can be established?
The challenge in now posed as an opportunity to re-
flect and to improve. 
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